QGEN
Qiagen
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 1
Revenue Beats Expectation
Bullish Abandoned Baby
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About QGEN
Qiagen N.V.
A leading provider of molecular diagnostics and sample preparation technologies for life sciences and molecular diagnostics markets
Life Science Tools and Services
Invalid Date
01/10/2018
New York Stock Exchange
5765
12-31
Common stock
Hulsterweg 82, 5912 PL Venlo, The Netherlands
--
Qiagen N.V. is a Dutch holding company whose subsidiary is the main provider of Sample and Assay Technologies. The company is a global leader in Sample to Insight solutions, serving more than 500,000 clients across two broad customer bases: Molecular Diagnostics (Human Healthcare) and Life Sciences (Academia, Pharma R&D and Industrial Applications, primarily Forensic Medicine). The company operates its products in more than 100 countries.
Company Financials
EPS
QGEN has released its 2024 Q4 earnings. EPS was reported at 0.61, versus the expected 0.62, missing expectations. The chart below visualizes how QGEN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
QGEN has released its 2024 Q4 earnings report, with revenue of 521.20M, reflecting a YoY change of 2.36%, and net profit of 88.32M, showing a YoY change of -9.57%. The Sankey diagram below clearly presents QGEN’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
